Tompkins Financial Corp Reduces Stake in Eli Lilly and Company $LLY

Tompkins Financial Corp cut its stake in shares of Eli Lilly and Company (NYSE:LLY) by 2.3% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 26,968 shares of the company’s stock after selling 629 shares during the period. Eli Lilly and Company accounts for about 2.2% of Tompkins Financial Corp’s investment portfolio, making the stock its 13th biggest holding. Tompkins Financial Corp’s holdings in Eli Lilly and Company were worth $31,204,000 as of its most recent filing with the SEC.

Other institutional investors have also recently made changes to their positions in the company. BlackRock Inc. raised its holdings in shares of Eli Lilly and Company by 1.6% in the 2nd quarter. BlackRock Inc. now owns 67,540,400 shares of the company’s stock valued at $81,009,981,000 after purchasing an additional 1,046,558 shares during the period. State Street Corp grew its holdings in Eli Lilly and Company by 1.7% during the second quarter. State Street Corp now owns 36,215,754 shares of the company’s stock worth $43,438,262,000 after purchasing an additional 605,752 shares during the period. Capital World Investors increased its position in Eli Lilly and Company by 0.4% during the fourth quarter. Capital World Investors now owns 15,031,750 shares of the company’s stock worth $16,154,619,000 after buying an additional 61,851 shares during the last quarter. Bank of America Corp DE acquired a new position in Eli Lilly and Company during the second quarter worth approximately $13,522,666,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in Eli Lilly and Company by 1.9% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 7,209,385 shares of the company’s stock valued at $8,647,153,000 after buying an additional 137,364 shares during the period. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Price Performance

Shares of NYSE:LLY traded up $11.17 during trading on Monday, reaching $1,154.02. 835,852 shares of the company traded hands, compared to its average volume of 2,976,150. The company’s 50 day moving average is $1,176.33 and its two-hundred day moving average is $1,089.48. The firm has a market capitalization of $1.09 trillion, a PE ratio of 38.77, a PEG ratio of 1.40 and a beta of 0.46. The company has a quick ratio of 1.00, a current ratio of 1.35 and a debt-to-equity ratio of 1.41. Eli Lilly and Company has a 52 week low of $783.85 and a 52 week high of $1,292.65.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Wednesday, August 5th. The company reported $8.38 EPS for the quarter, beating analysts’ consensus estimates of $6.40 by $1.98. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%.The business had revenue of $22.97 billion during the quarter, compared to the consensus estimate of $20.82 billion. During the same quarter in the previous year, the firm earned $6.31 earnings per share. Eli Lilly and Company’s revenue for the quarter was up 47.7% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. As a group, sell-side analysts predict that Eli Lilly and Company will post 36.66 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on LLY shares. UBS Group set a $1,376.00 price objective on shares of Eli Lilly and Company in a research report on Friday, August 7th. JPMorgan Chase & Co. boosted their price objective on Eli Lilly and Company from $1,400.00 to $1,500.00 and gave the stock an “overweight” rating in a report on Monday, September 28th. Royal Bank Of Canada lifted their price target on Eli Lilly and Company from $1,250.00 to $1,500.00 and gave the stock an “outperform” rating in a report on Wednesday, July 8th. Leerink Partners boosted their price target on Eli Lilly and Company from $1,119.00 to $1,232.00 and gave the company an “outperform” rating in a research note on Thursday, June 25th. Finally, Guggenheim upped their price objective on Eli Lilly and Company from $1,273.00 to $1,284.00 and gave the company a “buy” rating in a report on Friday, September 18th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-five have given a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $1,311.96.

Insider Buying and Selling at Eli Lilly and Company

In other news, EVP Anat Hakim sold 5,000 shares of the business’s stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $1,190.00, for a total value of $5,950,000.00. Following the completion of the transaction, the executive vice president directly owned 11,875 shares in the company, valued at approximately $14,131,250. The trade was a 29.63% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of the company’s stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the sale, the executive vice president directly owned 54,147 shares of the company’s stock, valued at approximately $63,628,139.70. This trade represents a 10.72% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 13,500 shares of company stock valued at $15,958,170 in the last ninety days. 0.14% of the stock is currently owned by company insiders.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: The FDA expanded approval of Jaypirca (pirtobrutinib) for previously untreated adults with chronic lymphocytic leukemia or small lymphocytic lymphoma without a 17p deletion. The decision, supported by Phase 3 results, expands Jaypirca’s addressable market and could accelerate sales growth. FDA Expands Approval for Eli Lilly Therapy in Untreated Leukemia Patients
• Positive Sentiment: Lilly’s experimental cancer drug olomorasib received FDA orphan-drug designation for pancreatic cancer. The designation may provide development incentives and highlights Lilly’s effort to broaden its oncology pipeline, though it is not an approval or proof of commercial success. Lilly Expands Oncology Footprint With FDA Win for Pancreatic Cancer Drug
• Positive Sentiment: Lilly expanded its collaboration and licensing agreement with Gate Bioscience to discover medicines aimed at difficult-to-drug proteins. It also partnered with Ginkgo Bioworks on drug discovery, strengthening external innovation efforts and potentially adding to its long-term pipeline. Gate Bioscience Expands Collaboration and License Agreement With Lilly
• Positive Sentiment: Early results for a next-generation obesity treatment targeting the amylin pathway renewed enthusiasm about Lilly’s ability to extend its leadership in the rapidly growing weight-loss market. Reports also point to strong patient growth and market-share gains versus Novo Nordisk. Eli Lilly Targets Amylin Pathway to Unlock Next Generation Obesity Drug Combinations
• Neutral Sentiment: Lilly will present 21 dermatology studies at the Fall Clinical Dermatology Conference, including data on Ebglyss, Taltz and Zepbound. The presentations could support future adoption, but they are not immediate revenue catalysts. Lilly Dermatology Portfolio Data
• Negative Sentiment: At roughly $1.09 trillion in market value and a forward earnings multiple near 39, Lilly’s valuation already reflects substantial obesity-drug growth. Any clinical, regulatory or competitive setback could therefore produce outsized downside.

Eli Lilly and Company Profile

Eli Lilly and Company is a global pharmaceutical company headquartered in Indianapolis, Indiana. Founded in 1876 by Colonel Eli Lilly, the company researches, develops, manufactures and markets medicines for a range of conditions, including diabetes, obesity, cancer, immunological disorders, neurological diseases and pain.

Its products include Mounjaro and Zepbound, which contain tirzepatide and are used for type 2 diabetes and chronic weight management, respectively. Other key medicines include Trulicity for diabetes, Verzenio for certain breast cancers, Taltz for inflammatory and autoimmune conditions, Humalog insulin, and Kisunla for early symptomatic Alzheimer’s disease.